Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy?
Corroborated by 1 source from 1 publisher
globalhealth5h ago
TL;DR
According to finance.yahoo.com, over the past year, the two leaders in the obesity drug market, Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), have lagged broader equities, though the latter has performed substantially worse than the former.